IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 29.885 USD -1.98%
Market Cap: 2.5B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

Relative Value

The Relative Value of one IDYA stock under the Base Case scenario is 11.692 USD. Compared to the current market price of 29.885 USD, IDEAYA Biosciences Inc is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IDYA Relative Value
Base Case
11.692 USD
Overvaluation 61%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
10
Median 3Y
27.7
Median 5Y
23.1
Industry
8.1
Forward
364.1
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-14.9
Industry
23
Forward
-12.6
vs History
vs Industry
6
Median 3Y
-13.8
Median 5Y
-8.9
Industry
23.4
vs History
vs Industry
5
Median 3Y
-13.6
Median 5Y
-8.5
Industry
27.3
vs History
53
vs Industry
25
Median 3Y
2.6
Median 5Y
2.4
Industry
2.6
vs History
0
vs Industry
10
Median 3Y
17.6
Median 5Y
12.6
Industry
8.1
Forward
236.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-8.3
Industry
4.3
Forward
-7.2
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-8
Industry
3.8
Forward
-6.9
vs History
vs Industry
7
Median 3Y
-9.7
Median 5Y
-4.5
Industry
6
vs History
vs Industry
7
Median 3Y
-9.6
Median 5Y
-4.3
Industry
3.8
vs History
60
vs Industry
21
Median 3Y
9.7
Median 5Y
9.3
Industry
4.8

Multiples Across Competitors

IDYA Competitors Multiples
IDEAYA Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
2.6B USD 658 -14.5 -7.7 -7.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average P/E: 211.8
Negative Multiple: -14.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average EV/EBITDA: 17.9
Negative Multiple: -7.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
Average EV/EBIT: 23.2
Negative Multiple: -7.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top